{"id":4922,"date":"2023-11-09T08:29:19","date_gmt":"2023-11-09T08:29:19","guid":{"rendered":"https:\/\/ctm.u-bourgogne.fr\/?p=4922"},"modified":"2024-01-29T08:43:40","modified_gmt":"2024-01-29T08:43:40","slug":"a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer","status":"publish","type":"post","link":"https:\/\/ctm.ube.fr\/index.php\/2023\/11\/09\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\/","title":{"rendered":"A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Roussot N, Fumet JD, Limagne E, Thibaudin M, Hervieu A, Hennequin A, Zanetta S, Dalens L, Fourrier T, Galland L, Jacob P, Bertaut A, Rederstorff E, Chevalier C, Ghirardi S, Gilbert E, Khoukaz A, Martin E, Nicolet C, Quivrin M, Thibouw D, Vulquin N, Truc G, Rouffiac M, Ghiringhelli F, Mirjolet C. A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer. <a href=\"https:\/\/bmccancer.biomedcentral.com\/\" title=\"\">BMC Cancer<\/a>. 2023 Nov 9;23(1):1080. doi: <a href=\"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-023-11534-6\" title=\"\">10.1186\/s12885-023-11534-6<\/a>. PMID: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37946136\/\" title=\"\">37946136<\/a>; PMCID: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10633948\/\" title=\"\">PMC10633948<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Trial registration:<\/strong> This study is registered on ClinicalTrials.gov: <a href=\"http:\/\/clinicaltrials.gov\/show\/NCT05259319\">NCT05259319<\/a>, since February 28th, 2022.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"715\" height=\"725\" src=\"https:\/\/ctm.u-bourgogne.fr\/wp-content\/uploads\/2024\/01\/image-1.png\" alt=\"\" class=\"wp-image-4923\" srcset=\"https:\/\/ctm.ube.fr\/wp-content\/uploads\/2024\/01\/image-1.png 715w, https:\/\/ctm.ube.fr\/wp-content\/uploads\/2024\/01\/image-1-296x300.png 296w\" sizes=\"(max-width: 715px) 100vw, 715px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Roussot N, Fumet JD, Limagne E, Thibaudin M, Hervieu A, Hennequin A, Zanetta S, Dalens L, Fourrier T, Galland L, Jacob P, Bertaut A, Rederstorff E, Chevalier C, Ghirardi S, Gilbert E, Khoukaz A, Martin E, Nicolet C, Quivrin M, Thibouw D, Vulquin N, Truc G, Rouffiac M, Ghiringhelli F, Mirjolet C. A phase I &#8230; <a title=\"A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer\" class=\"read-more\" href=\"https:\/\/ctm.ube.fr\/index.php\/2023\/11\/09\/a-phase-i-study-of-the-combination-of-atezolizumab-tiragolumab-and-stereotactic-body-radiation-therapy-in-patients-with-metastatic-multiorgan-cancer\/\" aria-label=\"En savoir plus sur A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer\">Lire la suite<\/a><\/p>\n","protected":false},"author":23,"featured_media":4926,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-4922","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/posts\/4922","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/comments?post=4922"}],"version-history":[{"count":1,"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/posts\/4922\/revisions"}],"predecessor-version":[{"id":4924,"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/posts\/4922\/revisions\/4924"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/media\/4926"}],"wp:attachment":[{"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/media?parent=4922"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/categories?post=4922"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ctm.ube.fr\/index.php\/wp-json\/wp\/v2\/tags?post=4922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}